AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Cybrexa Therapeutics to Present at the 2019 BIO International Convention

May 8, 2019

NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Per Hellsund, President and Chief Executive Officer of the Company, will present at the 2019 BIO International Convention being held on June 3-6, 2019 at the Pennsylvania Convention Center in Philadelphia, PA.

Mr. Hellsund will present a corporate overview on the Company’s platform, pipeline, and lead candidate CBX-11 (alphalexTM-rucaparib).

Details for the presentation are below:

Event: 2019 BIO International ConventionDate: Monday, June 3, 2019Time: 2:45 pm ETLocation: Pennsylvania Convention Center, Theatre 4

Members of the management team will be available for meetings at the BIO International Convention in Philadelphia. To arrange a meeting with management, please contact Janhavi Mohite at jmohite@theruthgroup.com or visit the BIO One-on-One Partnering webpage to schedule a meeting directly.

About the alphalex™ Technology Platform

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at http://www.cybrexa.com/our-technology/.

About Cybrexa

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

Contacts

The Ruth Group

Investor RelationsJanhavi Mohite jmohite@theruthgroup.com

Media RelationsKirsten Thomas kthomas@theruthgroup.com